Acorda Therapeutic (ACOR) October volatility at 93 into PDUFA
Down)
Acorda Therapeutic (Nasdaq: ACOR) : Acorda Therapeutic closed at $25.85. On May 6, the FDA granted priority review status to Fampridine-SR NDA, a novel therapy being developed to improve walking ability in people with multiple sclerosis. The PDUFA date for Fampridine-SR is October 22, 2009. ACOR July option implied volatility is at 72, August is at 82, October is at 93 and January is at 93; above its six-month average of 77, according to Track Data, suggesting larger price movement. Paul Foster
You May Also Be Interested In
- Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
- Cree (CREE) Volatility Elevated as CFO Slide Continues
- Vodafone (VOD) Volatility Pops Early, Shares Inch Higher
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
